Literature DB >> 28051841

A review of a national training initiative to increase provider use of MAT to address the opioid epidemic.

Frances R Levin1, Adam Bisaga1, Maria A Sullivan2,3, Arthur Robin Williams1, Kathryn Cates-Wessel4.   

Abstract

BACKGROUND AND OBJECTIVES: The Providers' Clinical Support System for Medication Assisted Treatment (PCSS-MAT) initiative focuses on training and mentoring health professionals in the treatment of opioid use disorders (OUD) using pharmacological strategies. Led by the American Academy of Addiction Psychiatry (AAAP), PCSS-MAT is a consortium representing four of the five national professional organizations authorized by DATA 2,000-AAAP, American Osteopathic Academy of Addiction Medicine, American Psychiatric Association, and American Society of Addiction Medicine. DATA organizations are authorized to train physicians to prescribe buprenorphine for OUD treatment. The primary aim of PCSS-MAT is to substantially increase evidence-based practices with medications for OUD.
METHODS: This review describes the development of PCSS-MAT, an ongoing national initiative funded by the Substance Abuse and Mental Health Services Administration (SAMHSA), to address the training needs posed by this critical public health problem. Core initiatives include: (1) Training and mentoring activities for primary care physicians; (2) Outreach to multidisciplinary professional organizations, (3) Creating a resource portal for families, patients, and communities for OUD treatment.
RESULTS: Educational outreach to providers addresses the needs of patients with OUD and common co-occurring psychiatric and medical disorders. DISCUSSION AND
CONCLUSIONS: The overall scope of PCSS-MAT is to increase access to evidence-based treatment of substance use disorders as a public health priority. Recently enacted legislation requires office-based opioid treatment programs to offer all Food and Drug Administration-approved (FDA) forms of MAT. SCIENTIFIC SIGNIFICANCE: Working with health care providers to effectively deliver MAT is key to integrating behavioral and physical medicine. (Am J Addict 2016;25:603-609).
© 2016 American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Year:  2016        PMID: 28051841      PMCID: PMC5486864          DOI: 10.1111/ajad.12454

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  29 in total

1.  Impact of interim methadone maintenance on HIV risk behaviors.

Authors:  Monique E Wilson; Robert P Schwartz; Kevin E O'Grady; Jerome H Jaffe
Journal:  J Urban Health       Date:  2010-07       Impact factor: 3.671

2.  The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.

Authors:  Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2010-02-01

3.  Trajectories of drug use and mortality outcomes among adults followed over 18 years.

Authors:  Stefan G Kertesz; Yulia Khodneva; Joshua Richman; Jalie A Tucker; Monika M Safford; Bobby Jones; Joseph Schumacher; Mark J Pletcher
Journal:  J Gen Intern Med       Date:  2012-01-25       Impact factor: 5.128

Review 4.  Training physicians to treat substance use disorders.

Authors:  Soteri Polydorou; Erik W Gunderson; Frances R Levin
Journal:  Curr Psychiatry Rep       Date:  2008-10       Impact factor: 5.285

5.  The increasing mortality burden of liver disease among opioid-dependent people: cohort study.

Authors:  Amy Gibson; Deborah Randall; Louisa Degenhardt
Journal:  Addiction       Date:  2011-10-17       Impact factor: 6.526

Review 6.  Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

Authors:  M Connock; A Juarez-Garcia; S Jowett; E Frew; Z Liu; R J Taylor; A Fry-Smith; E Day; N Lintzeris; T Roberts; A Burls; R S Taylor
Journal:  Health Technol Assess       Date:  2007-03       Impact factor: 4.014

7.  The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment.

Authors:  James E Egan; Paul Casadonte; Tracy Gartenmann; Judith Martin; Elinore F McCance-Katz; Julie Netherland; John A Renner; Linda Weiss; Andrew J Saxon; David A Fiellin
Journal:  J Gen Intern Med       Date:  2010-05-11       Impact factor: 5.128

Review 8.  Medication-assisted treatment with buprenorphine: assessing the evidence.

Authors:  Cindy Parks Thomas; Catherine Anne Fullerton; Meelee Kim; Leslie Montejano; D Russell Lyman; Richard H Dougherty; Allen S Daniels; Sushmita Shoma Ghose; Miriam E Delphin-Rittmon
Journal:  Psychiatr Serv       Date:  2014-02-01       Impact factor: 3.084

9.  Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds.

Authors:  Paul J Whelan; Kimberly Remski
Journal:  J Neurosci Rural Pract       Date:  2012-01

Review 10.  Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis.

Authors:  Georgie J MacArthur; Silvia Minozzi; Natasha Martin; Peter Vickerman; Sherry Deren; Julie Bruneau; Louisa Degenhardt; Matthew Hickman
Journal:  BMJ       Date:  2012-10-03
View more
  11 in total

1.  Been There, Done That: Lessons from Vancouver's Efforts to Stem the Tide of Overdose Deaths.

Authors:  Michael R Krausz; James S H Wong; Ehsan Moazen-Zadeh; Kerry L Jang
Journal:  Can J Psychiatry       Date:  2020-03-16       Impact factor: 4.356

2.  Young Adults Have Worse Outcomes Than Older Adults: Secondary Analysis of a Medication Trial for Opioid Use Disorder.

Authors:  Marc Fishman; Kevin Wenzel; Jennifer Scodes; Martina Pavlicova; Joshua D Lee; John Rotrosen; Edward Nunes
Journal:  J Adolesc Health       Date:  2020-08-29       Impact factor: 5.012

3.  Methadone Versus Buprenorphine for Opioid Use Dependence and Risk of Neonatal Abstinence Syndrome.

Authors:  Lara S Lemon; Steve N Caritis; Raman Venkataramanan; Robert W Platt; Lisa M Bodnar
Journal:  Epidemiology       Date:  2018-03       Impact factor: 4.822

4.  Acute Care, Prescription Opioid Use, and Overdose Following Discontinuation of Long-Term Buprenorphine Treatment for Opioid Use Disorder.

Authors:  Arthur Robin Williams; Hillary Samples; Stephen Crystal; Mark Olfson
Journal:  Am J Psychiatry       Date:  2019-12-02       Impact factor: 18.112

5.  Program development and implementation outcomes of a statewide addiction consultation service: Maryland Addiction Consultation Service (MACS).

Authors:  Sarah Sweeney; Kelly Coble; Elizabeth Connors; Kathleen Rebbert-Franklin; Christopher Welsh; Eric Weintraub
Journal:  Subst Abus       Date:  2020-08-19       Impact factor: 3.716

6.  How Physician Workforce Shortages Are Hampering the Response to the Opioid Crisis.

Authors:  Jennifer McNeely; Daniel Schatz; Mark Olfson; Noa Appleton; Arthur Robin Williams
Journal:  Psychiatr Serv       Date:  2021-09-15       Impact factor: 4.157

Review 7.  Attitudes of primary care physicians toward prescribing buprenorphine: a narrative review.

Authors:  Dexter L Louie; Mehret T Assefa; Mark P McGovern
Journal:  BMC Fam Pract       Date:  2019-11-15       Impact factor: 2.497

8.  "It's way more than just writing a prescription": A qualitative study of preferences for integrated versus non-integrated treatment models among individuals with opioid use disorder.

Authors:  Elizabeth C Saunders; Sarah K Moore; Olivia Walsh; Stephen A Metcalf; Alan J Budney; Patricia Cavazos-Rehg; Emily Scherer; Lisa A Marsch
Journal:  Addict Sci Clin Pract       Date:  2021-01-27

9.  "Now We Are Seeing the Tides Wash In": Trauma and the Opioid Epidemic in Rural Appalachian Ohio.

Authors:  Christine A Schalkoff; Emma L Richard; Hannah M Piscalko; Adams L Sibley; Daniel L Brook; Kathryn E Lancaster; William C Miller; Vivian F Go
Journal:  Subst Use Misuse       Date:  2021-03-07       Impact factor: 2.164

10.  Examination of Correlates of OUD Outcomes in Young Adults: Secondary Analysis From the XBOT Trial.

Authors:  Marc Fishman; Kevin Wenzel; Jennifer Scodes; Martina Pavlicova; Aimee N C Campbell; John Rotrosen; Edward Nunes
Journal:  Am J Addict       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.